Back to News
Market Impact: 0.2
Evaxion A/S to Present Biomarker Data from phase 2 Trial of EVX-01 at SITC 2026
Source: Nasdaq
Healthcare & Biotech
Evaxion A/S plans to present new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting in Phoenix, November 4–8, 2026. The article excerpt provides no data findings or trial outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
EVAX0.40
More News
- Evaxion to present phase 2 cancer vaccine trial data at SITC
- Midterm elections could jolt stocks if Democrats sweep Congress
- Bayer Raises Profit Outlook Helped by Strong Demand for Drugs
- Madrigal Pharma stock soars 10% on profit beat, strong Rezdiffra sales
- Pfizer earnings analysis: questions answered and next catalysts
- Vertex Pharmaceuticals earnings analysis: questions answered and next catalysts